Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

A phase 1 dose-escalation study of veliparib with bimonthly FOLFIRI in patients with advanced solid tumours.

Berlin J, Ramanathan RK, Strickler JH, Subramaniam DS, Marshall J, Kang YK, Hetman R, Dudley MW, Zeng J, Nickner C, Xiong H, Komarnitsky P, Shepherd SP, Hurwitz H, Lenz HJ.

Br J Cancer. 2018 Apr;118(7):938-946. doi: 10.1038/s41416-018-0003-3. Epub 2018 Mar 12.

2.

Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study.

Han HS, Diéras V, Robson M, Palácová M, Marcom PK, Jager A, Bondarenko I, Citrin D, Campone M, Telli ML, Domchek SM, Friedlander M, Kaufman B, Garber JE, Shparyk Y, Chmielowska E, Jakobsen EH, Kaklamani V, Gradishar W, Ratajczak CK, Nickner C, Qin Q, Qian J, Shepherd SP, Isakoff SJ, Puhalla S.

Ann Oncol. 2018 Jan 1;29(1):154-161. doi: 10.1093/annonc/mdx505.

3.

Smoking History Predicts Sensitivity to PARP Inhibitor Veliparib in Patients with Advanced Non-Small Cell Lung Cancer.

Reck M, Blais N, Juhasz E, Gorbunova V, Jones CM, Urban L, Orlov S, Barlesi F, Kio E, Keilholz U, Qin Q, Qian J, Nickner C, Dziubinski J, Xiong H, Mittapalli RK, Dunbar M, Ansell P, He L, McKee M, Giranda V, Ramalingam SS.

J Thorac Oncol. 2017 Jul;12(7):1098-1108. doi: 10.1016/j.jtho.2017.04.010. Epub 2017 Apr 29.

4.

Randomized, Placebo-Controlled, Phase II Study of Veliparib in Combination with Carboplatin and Paclitaxel for Advanced/Metastatic Non-Small Cell Lung Cancer.

Ramalingam SS, Blais N, Mazieres J, Reck M, Jones CM, Juhasz E, Urban L, Orlov S, Barlesi F, Kio E, Keiholz U, Qin Q, Qian J, Nickner C, Dziubinski J, Xiong H, Ansell P, McKee M, Giranda V, Gorbunova V.

Clin Cancer Res. 2017 Apr 15;23(8):1937-1944. doi: 10.1158/1078-0432.CCR-15-3069. Epub 2016 Oct 10.

5.

Comparative study of cyclosporine and tacrolimus vs newer immunosuppressants mycophenolate mofetil and rapamycin on coronary endothelial function.

Jeanmart H, Malo O, Carrier M, Nickner C, Desjardins N, Perrault LP.

J Heart Lung Transplant. 2002 Sep;21(9):990-8.

PMID:
12231370
6.

Improved preservation of coronary endothelial function with Celsior compared with blood and crystalloid solutions in heart transplantation.

Perrault LP, Nickner C, Desjardins N, Dumont E, Thai P, Carrier M.

J Heart Lung Transplant. 2001 May;20(5):549-58.

PMID:
11343982
7.

Comparative study of CSA and FK506 versus newer immunosuppressive drugs MMF and rapamycin on coronary endothelial function in vitro.

Jeanmart H, Perrault LP, Carrier M, Cartier R, Nickner C.

J Heart Lung Transplant. 2001 Feb;20(2):235. No abstract available.

PMID:
11250453
8.

Effects of occlusion devices for minimally invasive coronary artery bypass surgery on coronary endothelial function of atherosclerotic arteries.

Perrault LP, Desjardins N, Nickner C, Geoffroy P, Tanguay J, Carrier M.

Heart Surg Forum. 2000;3(4):287-92.

PMID:
11178289
9.

Effects on coronary endothelial function of the Cohn stabilizer for beating heart bypass operations.

Perrault LP, Nickner C, Desjardins N, Carrier M.

Ann Thorac Surg. 2000 Sep;70(3):1111-4.

PMID:
11016390

Supplemental Content

Loading ...
Support Center